Terms: = Colorectal cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Prognosis
734 results:
1. The Relationship of Microsatellite Instability with braf and p53 Mutations and Histopathological Parameters in colorectal Adenocarcinoma.
Gündoğar Ö; Bektaş S; Yıldırım E; Gönüllü D
Ann Ital Chir; 2024; 95(2):181-191. PubMed ID: 38684491
[TBL] [Abstract] [Full Text] [Related]
2. [colorectal adenocarcinoma with enteroblastic differentiation: a clinicopathological analysis of eight cases].
Wang Q; Zhang Y; Tan C; Ni SJ; Huang D; Chang B; Sheng WQ; Wang L
Zhonghua Bing Li Xue Za Zhi; 2024 Apr; 53(4):370-376. PubMed ID: 38556821
[No Abstract] [Full Text] [Related]
3. Dynamic ctDNA-based analysis of drug-resistant gene alterations at RAS/braf wild-type metastatic colorectal cancer patients after cetuximab plus chemotherapy as the first-line treatment.
Zhou YW; Zhao X; Ni L; Cao P; Leng WB; Zhu Q; Gou HF; Zhang J; Li XF; Qiu M
Int Immunopharmacol; 2024 Apr; 131():111887. PubMed ID: 38503018
[TBL] [Abstract] [Full Text] [Related]
4. BCL-X
Jenkins LJ; Luk IY; Chionh F; Tan T; Needham K; Ayton J; Reehorst CM; Vukelic N; Sieber OM; Mouradov D; Gibbs P; Williams DS; Tebbutt NC; Desai J; Hollande F; Dhillon AS; Lee EF; Merino D; Fairlie WD; Mariadason JM
Cell Death Dis; 2024 Mar; 15(3):183. PubMed ID: 38429301
[TBL] [Abstract] [Full Text] [Related]
5. colorectal neuroendocrine carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm: Prognostic factors and PD-L1 expression.
Ho YH; Hsu CY; Yau Li AF; Liang WY
Hum Pathol; 2024 Mar; 145():80-85. PubMed ID: 38423221
[TBL] [Abstract] [Full Text] [Related]
6. Clinical and genetic factors associated with tumor response to neoadjuvant (chemo)radiotherapy, survival and recurrence risk in rectal cancer.
Hammarström K; Nunes L; Mathot L; Mezheyeuski A; Lundin E; Korsavidou Hult N; Imam I; Osterlund E; Sjöblom T; Glimelius B
Int J Cancer; 2024 Jul; 155(1):40-53. PubMed ID: 38376070
[TBL] [Abstract] [Full Text] [Related]
7. Integrating cfDNA liquid biopsy and organoid-based drug screening reveals PI3K signaling as a promising therapeutic target in colorectal cancer.
Yang H; Xiao X; Zeng L; Zeng H; Zheng Y; Wang J; Li G; Dai W; He Y; Wang S; Peng J; Chen W
J Transl Med; 2024 Feb; 22(1):132. PubMed ID: 38310289
[TBL] [Abstract] [Full Text] [Related]
8. Assessing the Therapeutic Impacts of HAMLET and FOLFOX on braf-Mutated colorectal cancer: A Study of cancer Cell Survival and Mitochondrial Dynamics In Vitro and Ex Vivo.
Žilinskas J; Stukas D; Jasukaitienė A; Žievytė I; Balion Z; Šapauskienė J; Banienė R; Paužas H; Lizdenis P; Čėsna V; Dambrauskas Ž; Gulbinas A; Tamelis A
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256402
[No Abstract] [Full Text] [Related]
9. Genetic Polymorphisms and Tumoral Mutational Profiles over Survival in Advanced colorectal cancer Patients: An Exploratory Study.
Cayún JP; Cerpa LC; Colombo A; Cáceres DD; Leal JL; Reyes F; Gutiérrez-Cáceres C; Calfunao S; Varela NM; Quiñones LA
Curr Oncol; 2024 Jan; 31(1):274-295. PubMed ID: 38248103
[TBL] [Abstract] [Full Text] [Related]
10. The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review.
Ciardiello D; Mauri G; Sartore-Bianchi A; Siena S; Zampino MG; Fazio N; Cervantes A
Cancer Treat Rev; 2024 Mar; 124():102683. PubMed ID: 38237253
[TBL] [Abstract] [Full Text] [Related]
11. colorectal Carcinoma With Sarcomatoid Components: Report of 15 Cases and Literature Review of an Exceedingly Rare Carcinoma Subtype.
Golconda U; McHugh KE; Allende DS; Collins K; Henn P; Lacambra M; Bejarano PA; Groisman GM; Loughrey MB; Monappa V; Zhang X; Hornick JL; Gonzalez RS
Am J Surg Pathol; 2024 Apr; 48(4):465-474. PubMed ID: 38155543
[TBL] [Abstract] [Full Text] [Related]
12. Targeted Mass Spectrometry Analyses of Somatic Mutations in colorectal cancer Specimens Using Differential Ion Mobility.
Wu Z; Bonneil É; Belford M; Boeser C; Dunyach JJ; Thibault P
J Proteome Res; 2024 Feb; 23(2):644-652. PubMed ID: 38153093
[TBL] [Abstract] [Full Text] [Related]
13. Real-World Outcomes of First-Line FOLFIRI Plus Bevacizumab with Irinotecan Dose Escalation versus FOLFOXIRI Plus Bevacizumab in
Tsai HL; Huang CW; Chen YC; Su WC; Chang TK; Chen PJ; Li CC; Chang YT; Wang JY
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138211
[No Abstract] [Full Text] [Related]
14. Site specific genetic differences in colorectal cancer via Next-Generation-Sequencing using a multigene panel.
Rencuzogullari A; Bisgin A; Erdogan KE; Gumus S; Yalav O; Boga I; Sonmezler O; Eray IC
Ann Ital Chir; 2023; 94():605-611. PubMed ID: 38131395
[TBL] [Abstract] [Full Text] [Related]
15. Regorafenib therapy as a third-line treatment for metastatic colorectal cancer: A single center long term experience.
Ozkan M; Oflazoglu U; Yildiz Y; Güc ZG; Salman T; Ünal S; Kücükzeybek Y; Alacacioglu A
Medicine (Baltimore); 2023 Dec; 102(50):e36435. PubMed ID: 38115370
[TBL] [Abstract] [Full Text] [Related]
16. Opposing roles by KRAS and braf mutation on immune cell infiltration in colorectal cancer - possible implications for immunotherapy.
Edin S; Gylling B; Li X; Stenberg Å; Löfgren-Burström A; Zingmark C; van Guelpen B; Ljuslinder I; Ling A; Palmqvist R
Br J Cancer; 2024 Jan; 130(1):143-150. PubMed ID: 38040818
[TBL] [Abstract] [Full Text] [Related]
17. DNA Mutational Profiling in Patients With colorectal cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations.
Innocenti F; Mu W; Qu X; Ou FS; Kabbarah O; Blanke CD; Venook AP; Lenz HJ; Rashid NU
J Clin Oncol; 2024 Feb; 42(4):399-409. PubMed ID: 37992266
[TBL] [Abstract] [Full Text] [Related]
18. Immune checkpoint inhibitors in
Kassab R; Khalil MA; Kassab J; Kourie HR
Future Oncol; 2023 Nov; 19(36):2417-2424. PubMed ID: 37990891
[TBL] [Abstract] [Full Text] [Related]
19. Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
Lu X; Li Y; Li Y; Zhang X; Shi J; Feng H; Yu Z; Gao Y
BMC Cancer; 2023 Nov; 23(1):1117. PubMed ID: 37974093
[TBL] [Abstract] [Full Text] [Related]
20. Detection and clinical significance of CEACAM5 methylation in colorectal cancer patients.
Huang SC; Chang SC; Liao TT; Yang MH
Cancer Sci; 2024 Jan; 115(1):270-282. PubMed ID: 37942534
[TBL] [Abstract] [Full Text] [Related]
[Next]